FDA to Rule on Merck Keytruda Combo by May

Jan 15, 2017

Merck & Co. announced that the U.S. FDA has accepted its application for a new Keytruda-plus-chemotherapy combo and granted the drugmaker priority review.

The FDA will decide by May 10 whether to approve the Keytruda combination therapy, giving Merck a huge leg-up on immunotherapy competitors, including Roche and BMS.

This first application for Keytruda as a combination treatment would include patients with metastatic or advanced non-squamous non-small cell lung cancer (NSCLC) regardless of PD-L1 expression level, opening up a much larger market for the medicine.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments